Allegheny General is one of more than 200 sites across 17 countries around the world involved in the C. diff vaccine clinical trial, a Phase III randomized, observer-blind, placebo-controlled study.
Patients interested in enrolling in the study should be age 50 or older and planning an upcoming hospitalization of more than 72 hours for a surgical procedure. Also eligible for the study are patients in this age group who have been hospitalized at least twice, each time lasting more than 24 hours, and have received systemic antibiotics in the past year.
For more information about how to enroll, click here.
More articles on C. diff:
How South Seminole Hospital cut C. diff infections in half
10 recent stories, studies on C. diff
A non-antibiotic drug could work against C. diff, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
